Inhibition of B-cells has proven to be effective for treatment of SLE as evidenced by the approval of belimumab and the efficacy seen for the BAFF/APRIL inhibitor, atacicept. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.